CLINICAL TRIALS PROFILE FOR PATADAY ONCE DAILY RELIEF

All Clinical Trials for Pataday Once Daily Relief

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00534794 ↗	Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis	Completed	Merck Sharp & Dohme Corp.	Phase 4	2007-10-01	The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
NCT01272089 ↗	A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis	Completed	Alcon Research	Phase 4	2011-05-01	The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study.
NCT01450176 ↗	Comparing Patient Satisfaction With Pataday or Bepreve	Completed	McCabe Vision Center	N/A	2011-09-01	The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID).
NCT01470118 ↗	A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis	Completed	Allergan	Phase 4	2011-10-01	This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
NCT01732757 ↗	A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis	Completed	Allergan	Phase 4	2012-11-01	This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
NCT05265910 ↗	A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis	Recruiting	Andover Research Eye Institute	Phase 4	2021-12-14	This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.

Clinical Trial Conditions for Pataday Once Daily Relief

Condition Name

Condition Name for Pataday Once Daily Relief
Intervention	Trials
Allergic Conjunctivitis	4
Conjunctivitis, Allergic	2
Eye Allergies	1

Condition MeSH

Condition MeSH for Pataday Once Daily Relief
Intervention	Trials
Conjunctivitis, Allergic	6
Conjunctivitis	6
Drug Hypersensitivity	1
Hypersensitivity	1

Clinical Trial Locations for Pataday Once Daily Relief

Trials by Country

Trials by Country for Pataday Once Daily Relief
Location	Trials
United States	6
India	1

Trials by US State

Trials by US State for Pataday Once Daily Relief
Location	Trials
Massachusetts	3
Tennessee	2
Pennsylvania	1

Clinical Trial Progress for Pataday Once Daily Relief

Clinical Trial Phase

Clinical Trial Phase for Pataday Once Daily Relief
Clinical Trial Phase	Trials
Phase 4	6
N/A	1

Clinical Trial Status

Clinical Trial Status for Pataday Once Daily Relief
Clinical Trial Phase	Trials
Completed	5
Recruiting	2

Clinical Trial Sponsors for Pataday Once Daily Relief

Sponsor Name

Sponsor Name for Pataday Once Daily Relief
Sponsor	Trials
Allergan	2
Andover Research Eye Institute	2
Merck Sharp & Dohme Corp.	1

Sponsor Type

Sponsor Type for Pataday Once Daily Relief
Sponsor	Trials
Industry	6
Other	1